PT106094A - Administração por inalação de formulações com dose elevada - Google Patents

Administração por inalação de formulações com dose elevada Download PDF

Info

Publication number: PT106094A
Authority: PT; Portugal
Prior art keywords: inhaler; formulation; pharmaceutical; medicament; buffer
Prior art date: 2012-01-13

Application number

PT106094A

Other languages

English (en)

Portuguese (pt)

Inventor

Pedro Jorge Mendes

Jason Suggett

Phillip Nelson

Ana Goncalves

Original Assignee

Hovione Farmaciencia S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-13

Filing date

2012-01-13

Publication date

2013-07-15

2012-01-13 Application filed by Hovione Farmaciencia S A filed Critical Hovione Farmaciencia S A

2012-01-13 Priority to PT106094A priority Critical patent/PT106094A/pt

2013-01-14 Priority to PCT/GB2013/000015 priority patent/WO2013104892A1/fr

2013-07-15 Publication of PT106094A publication Critical patent/PT106094A/pt

Links

239000000203 mixture Substances 0.000 title claims abstract description 93
238000009472 formulation Methods 0.000 claims abstract description 69
239000002775 capsule Substances 0.000 claims abstract description 16
239000000843 powder Substances 0.000 claims abstract description 15
150000001875 compounds Chemical class 0.000 claims abstract description 11
238000011282 treatment Methods 0.000 claims abstract description 7
238000000034 method Methods 0.000 claims description 28
239000000872 buffer Substances 0.000 claims description 26
239000003795 chemical substances by application Substances 0.000 claims description 25
239000008194 pharmaceutical composition Substances 0.000 claims description 21
239000003814 drug Substances 0.000 claims description 17
230000008569 process Effects 0.000 claims description 12
238000001035 drying Methods 0.000 claims description 9
229960003722 doxycycline Drugs 0.000 claims description 8
XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 8
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
239000000243 solution Substances 0.000 claims description 5
208000019693 Lung disease Diseases 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
230000002685 pulmonary effect Effects 0.000 claims description 4
201000003883 Cystic fibrosis Diseases 0.000 claims description 3
239000007979 citrate buffer Substances 0.000 claims description 3
229940112141 dry powder inhaler Drugs 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
238000001694 spray drying Methods 0.000 claims description 2
201000010099 disease Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
238000009413 insulation Methods 0.000 claims 2
239000004280 Sodium formate Substances 0.000 claims 1
229910000831 Steel Inorganic materials 0.000 claims 1
230000003213 activating effect Effects 0.000 claims 1
238000005520 cutting process Methods 0.000 claims 1
239000000839 emulsion Substances 0.000 claims 1
230000006698 induction Effects 0.000 claims 1
230000003902 lesion Effects 0.000 claims 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims 1
235000019254 sodium formate Nutrition 0.000 claims 1
239000012064 sodium phosphate buffer Substances 0.000 claims 1
239000010959 steel Substances 0.000 claims 1
230000008961 swelling Effects 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
239000008186 active pharmaceutical agent Substances 0.000 abstract description 10
239000008177 pharmaceutical agent Substances 0.000 abstract 1
239000002245 particle Substances 0.000 description 9
230000003115 biocidal effect Effects 0.000 description 8
239000004480 active ingredient Substances 0.000 description 6
239000006185 dispersion Substances 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
239000003172 expectorant agent Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
229940066491 mucolytics Drugs 0.000 description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
239000001509 sodium citrate Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000035515 penetration Effects 0.000 description 3
230000035699 permeability Effects 0.000 description 3
OMDMTHRBGUBUCO-IUCAKERBSA-N (1s,5s)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-ol Chemical compound CC1=CC[C@H](C(C)(C)O)C[C@@H]1O OMDMTHRBGUBUCO-IUCAKERBSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
239000002253 acid Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000010419 fine particle Substances 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229960003870 bromhexine Drugs 0.000 description 1
OJGDCBLYJGHCIH-UHFFFAOYSA-N bromhexine Chemical compound C1CCCCC1N(C)CC1=CC(Br)=CC(Br)=C1N OJGDCBLYJGHCIH-UHFFFAOYSA-N 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
239000002781 deodorant agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000005802 health problem Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000003562 lightweight material Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000003801 milling Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
230000000420 mucociliary effect Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000003016 pheromone Substances 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
229960000230 sobrerol Drugs 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229910021654 trace metal Inorganic materials 0.000 description 1
OMDMTHRBGUBUCO-UHFFFAOYSA-N trans-sobrerol Natural products CC1=CCC(C(C)(C)O)CC1O OMDMTHRBGUBUCO-UHFFFAOYSA-N 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT106094A 2012-01-13 2012-01-13 Administração por inalação de formulações com dose elevada PT106094A (pt)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
PT106094A PT106094A (pt)	2012-01-13	2012-01-13	Administração por inalação de formulações com dose elevada
PCT/GB2013/000015 WO2013104892A1 (fr)	2012-01-13	2013-01-14	Application de composés à fortes doses par inhalation

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PT106094A PT106094A (pt)	2012-01-13	2012-01-13	Administração por inalação de formulações com dose elevada

Publications (1)

Publication Number	Publication Date
PT106094A true PT106094A (pt)	2013-07-15

Family

ID=47605587

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT106094A PT106094A (pt)	2012-01-13	2012-01-13	Administração por inalação de formulações com dose elevada

Country Status (2)

Country	Link
PT (1)	PT106094A (fr)
WO (1)	WO2013104892A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2625260T5 (es)	2009-03-26	2020-07-29	Pulmatrix Operating Co Inc	Formulaciones de polvo seco y métodos para el tratamiento de enfermedades pulmonares
CN103200938B (zh)	2010-08-30	2018-07-31	普马特里克斯营业公司	干燥粉末配方及用于治疗肺部疾病的方法
BR112013007304B1 (pt)	2010-09-29	2021-12-14	Pulmatrix, Inc.	Pós secos de cátion de metal monovalente para inalação
PT3470057T (pt)	2010-09-29	2021-12-03	Pulmatrix Operating Co Inc	Pós secos catiónicos compreendendo sais de magnésio
CN107596518B (zh)	2012-02-29	2021-04-23	普马特里克斯营业公司	可吸入干粉剂
AU2014248455B2 (en)	2013-04-01	2018-12-06	Pulmatrix Operating Company, Inc.	Tiotropium dry powders
SG11201700621XA (en)	2014-07-25	2017-02-27	Agency Science Tech & Res	Antibiotic compositions for treating bacterial infections
CN109745301A (zh) *	2017-11-08	2019-05-14	北京盈科瑞创新药物研究有限公司	一种羧甲司坦雾化吸入用溶液制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007061454A1 (fr) *	2005-11-22	2007-05-31	Medpointe Healthcare Inc.	Compositions comprenant de l'azelastine et procedes d'utilisation de celles-ci
EP1827499A1 (fr) *	2004-11-24	2007-09-05	MedPointe Healthcare Inc.	Compositions comportant de l'azelastine et leurs procedes d'utilisation
US20100152147A1 (en) *	2004-11-24	2010-06-17	Meda Pharmaceuticals Inc.	Compositions Comprising Azelastine and Methods of Use Thereof
US20110259328A1 (en) *	2010-04-26	2011-10-27	Hovione International Ltd.	Simple capsule-based inhaler

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1242211A (en)	1967-08-08	1971-08-11	Fisons Pharmaceuticals Ltd	Pharmaceutical composition
US20030113273A1 (en) *	1996-06-17	2003-06-19	Patton John S.	Methods and compositions for pulmonary delivery of insulin
US6858199B1 (en)	2000-06-09	2005-02-22	Advanced Inhalation Research, Inc.	High efficient delivery of a large therapeutic mass aerosol
US20070123449A1 (en) *	2005-11-01	2007-05-31	Advanced Inhalation Research, Inc.	High load particles for inhalation having rapid release properties
AU2008279129A1 (en) *	2007-07-24	2009-01-29	Nexbio, Inc.	Technology for the preparation of microparticles
CN102448439A (zh) *	2009-03-26	2012-05-09	普马特里克斯公司	用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
GB201021186D0 (en)	2010-12-14	2011-01-26	Novabiotics Ltd	Composition

2012
- 2012-01-13 PT PT106094A patent/PT106094A/pt not_active Application Discontinuation
2013
- 2013-01-14 WO PCT/GB2013/000015 patent/WO2013104892A1/fr not_active Ceased

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1827499A1 (fr) *	2004-11-24	2007-09-05	MedPointe Healthcare Inc.	Compositions comportant de l'azelastine et leurs procedes d'utilisation
KR20070104884A (ko) *	2004-11-24	2007-10-29	메드포인트 헬쓰케어 인크.	아젤라스틴을 포함하는 조성물 및 이의 사용 방법
MX2007006233A (es) *	2004-11-24	2007-11-23	Medpointe Healthcare Inc	Composiciones que comprenden azelastina y metodos de uso de la misma.
US20100152147A1 (en) *	2004-11-24	2010-06-17	Meda Pharmaceuticals Inc.	Compositions Comprising Azelastine and Methods of Use Thereof
WO2007061454A1 (fr) *	2005-11-22	2007-05-31	Medpointe Healthcare Inc.	Compositions comprenant de l'azelastine et procedes d'utilisation de celles-ci
TW201141557A (en) *	2010-04-26	2011-12-01	Hovione Int Ltd	A simple capsule-based inhaler
WO2011135327A1 (fr) *	2010-04-26	2011-11-03	Hovione International Ltd.	Inhalateur simple à capsules
CA2791149A1 (fr) *	2010-04-26	2011-11-03	Hovione International Ltd.	Inhalateur a capsule a deux parties ayant un dispositif de coupe de capsule
US20110259328A1 (en) *	2010-04-26	2011-10-27	Hovione International Ltd.	Simple capsule-based inhaler
AR080968A1 (es) *	2010-04-26	2012-05-23	Hovione Int Ltd	Inhalador individual con capsula
PT105065B (pt) *	2010-04-26	2012-07-31	Hovione Farmaciencia S A	Um inalador simples de cápsulas
AU2011247073A1 (en) *	2010-04-26	2012-08-30	Hovione Technology Limited	A simple capsule-based inhaler
SG183307A1 (en) *	2010-04-26	2012-09-27	Hovione Int Ltd	A simple capsule-based inhaler
CO6561767A2 (es) *	2010-04-26	2012-11-15	Hovione Int Ltd	Inhalador individual con cápsula
EP2536460A1 (fr) *	2010-04-26	2012-12-26	Hovione International Ltd.	Inhalateur simple à capsules
CN102933244A (zh) *	2010-04-26	2013-02-13	霍维翁国际有限公司	简单的基于囊的吸入器
KR20130028722A (ko) *	2010-04-26	2013-03-19	호비온 인터내셔날 리미티드	간소형 캡슐-기반 흡입기
AU2011247073B2 (en) *	2010-04-26	2013-03-21	Hovione Technology Limited	A simple capsule-based inhaler

Also Published As

Publication number	Publication date
WO2013104892A8 (fr)	2013-09-19
WO2013104892A1 (fr)	2013-07-18

Legal Events

Date	Code	Title	Description
2013-07-15	BB1A	Laying open of patent application	Effective date: 20130517
2014-05-20	FA1A	Withdrawal of application (patent)	Effective date: 20140515

Publication	Publication Date	Title
PT106094A (pt)	2013-07-15	Administração por inalação de formulações com dose elevada
JP6824434B2 (ja)	2021-02-03	ネココロナウイルス感染を処置する方法
CN1187044C (zh)	2005-02-02	可储存的含福莫特罗的活性物质浓缩液
KR100686901B1 (ko)	2007-02-26	점막 투여용 약제학적 조성물
CN111297838A (zh)	2020-06-19	一种抗病毒药物的吸入喷雾剂
BRPI0406674B1 (pt)	2015-12-22	composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição
WO2022212399A1 (fr)	2022-10-06	Composés antiparasitaires pour le traitement et la prévention de maladies virales
CN103260615A (zh)	2013-08-21	包含扎那米韦的低剂量药物组合物
WO2015027848A1 (fr)	2015-03-05	Méthode pour administrer une formulation comportant du peramivir et/ou un dérivé correspondant
JP5373616B2 (ja)	2013-12-18	鳥インフルエンザウイルス感染の予防的治療のためのポリｉｃｌｃカプセル化リポソーム
EP1648430A1 (fr)	2006-04-26	Traitement de l'ejaculation precoce
CN101836951A (zh)	2010-09-22	一种含盐酸氨溴索的口服溶液及其制备方法
CN1179726C (zh)	2004-12-15	柚皮苷在制备支持性治疗非典型性肺炎药物中的应用
US12350279B2 (en)	2025-07-08	Nasal rinse compositions and methods
CN112839633A (zh)	2021-05-25	包含药剂的低共熔溶剂及其制造方法和用途
CN102172348A (zh)	2011-09-07	固体的磷酸奥司他韦药物组合物
CN101897720B (zh)	2015-09-09	一种治疗呼吸道疾病的药物组合物
CN105456240B (zh)	2019-06-25	氨溴索沙丁胺醇气雾剂
CN105362226B (zh)	2019-06-25	氨溴索沙丁胺醇气雾剂的制备方法
JPH09227373A (ja)	1997-09-02	抗インフルエンザウイルス剤
JP2006008540A (ja)	2006-01-12	風邪薬
BR0008442B1 (pt)	2014-04-01	Composição farmacêutica na forma de formulação efervescente, contendo metamizol
CN105326790B (zh)	2018-06-05	氨溴索沙丁胺醇溶液剂的制备方法
CN105326789A (zh)	2016-02-17	氨溴索沙丁胺醇溶液剂
AU2005100183A4 (en)	2005-04-07	Treatment of premature ejaculation